TrialThe Lancet. Oncology2017

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.

David Cunningham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.